Elucidating molecular mechanisms of acquired resistance to BRAF inhibitors in melanoma using a microfluidic device and deep sequencing

BRAF inhibitors (e.g., vemurafenib) are widely used to treat metastatic melanoma with the BRAF V600E mutation. The initial response is often dramatic, but treatment resistance leads to disease progression in the majority of cases. Although secondary mutations in the mitogen-activated protein kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Jiyeon, Jung, Yeonjoo, Jun, Yukyung, Park, Sungsu, Lee, Sanghyuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korea Genome Organization 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042304/
https://www.ncbi.nlm.nih.gov/pubmed/33840166
http://dx.doi.org/10.5808/gi.20074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042304/
https://www.ncbi.nlm.nih.gov/pubmed/33840166
http://dx.doi.org/10.5808/gi.20074

Ejemplares similares